Wanbangde Pharmaceutical (SHE:002082) said its Alzheimer's disease drug project has been selected for China's national major science and technology program for innovative drug development.
The project, led by its subsidiary Wanbangde Pharma, focuses on the industrial production and clinical trials of huperzine A sustained-release tablets, according to a Saturday filing with the Shenzhen bourse.
Shares of the pharmaceutical company's shares closed 10% higher Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments